The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
Abstract Background Epidermal growth factor receptor (EGFR) mutations are key drivers in a significant portion of non‐small‐cell lung cancer (NSCLC) patients. While third‐generation EGFR‐tyrosine kinase inhibitors (TKIs) such as osimertinib have demonstrated efficacy, the management of patients who...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wiley
2024-08-01
|
| シリーズ: | Thoracic Cancer |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1111/1759-7714.15399 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|